Overview

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2026-10-15
Target enrollment:
Participant gender:
Summary
The study is a 2-part study of AUM001 alone on in combination with Pembrolizumab/Irinotecan in patients with CRC.
Phase:
Phase 2
Details
Lead Sponsor:
AUM Biosciences Pte Ltd
Treatments:
Irinotecan
Pembrolizumab